HUMA•Humacyte received a U.S. patent covering Symvess and other bioengineered human tissues, including manufacturing, sterilization, storage and shipping methods, extending protection for key platform technologies into 2043.
The patent covers key manufacturing and sterilization processes, as well as storage and shipping methods for Symvess and other bioengineered human tissues. Humacyte said it extends protection for key platform technologies into 2043.
Symvess received FDA approval for extremity vascular trauma in December 2024. Humacyte plans to submit a supplemental application for dialysis access this year.
